Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM EDTBiogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.
BIIB reported Q3 EPS of $4.77 to beat the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
As far as full-year guidance is concerned, Biogen projects FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61.... More
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM EDTEarlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More
